• HIV Diagnostics Survey

    HIV Diagnostics Survey

    The 2014 HIV Diagnostic Survey assessed testing practices in public health labs as of that date. More.
Our Work

APHL examines public health lab science, practice and management in its technical publications.


 

 

Hemoglobinopathieshttp://redesign.dev.aphl.org/reports-briefs/Lists/Highlighted Content/DispForm.aspx?ID=2Hemoglobinopathies<img alt="" src="/PublishingImages/Reports%20and%20Briefs%203.gif" style="BORDER:0px solid;" />http://www.aphl.org/AboutAPHL/publications/Documents/NBS_HemoglobinopathyTesting_122015.pdf, Hemoglobinopathies: Current Practices for Screening, Confirmation and Follow-up
Nat'l Biomonitoring Plan http://redesign.dev.aphl.org/reports-briefs/Lists/Highlighted Content/DispForm.aspx?ID=1Nat'l Biomonitoring Plan <img alt="" src="/PublishingImages/Reports%20and%20Briefs%202.gif" style="BORDER:0px solid;" />http://www.aphl.org/AboutAPHL/publications/Documents/EH_National_Biomonitoring_Plan_112015.pdf, National Biomonitoring Plan
BGT Checklist http://redesign.dev.aphl.org/reports-briefs/Lists/Highlighted Content/DispForm.aspx?ID=3BGT Checklist <img alt="" src="/PublishingImages/Reports-and-Briefs-4.gif" style="BORDER:0px solid;" />http://www.aphl.org/AboutAPHL/publications/Documents/QS_BGT_Checklist_112015.pdf, Crosswalk of CLIA Requirements and Recommended Practices in Biochemical Genetic Testing Laboratories

 

 

2015 All-Hazards Survey Reporthttp://redesign.dev.aphl.org/aboutAPHL/publications/Documents/PHPR-2015-All-Hazards-52016-digital.pdf2015 All-Hazards Survey ReportEach year, APHL surveys PHLs to assess their readiness to respond to threats and identify challenges that affect rapid response. This year's survey covers the 12-month period from 7/1/14 - 6/30/15, representing FY14 CDC PHEP Cooperative Agreement, BP 3.
Guidance for State Medical Cannabis Testinghttp://redesign.dev.aphl.org/aboutAPHL/publications/Documents/EH-Guide-State-Med-Cannabis-052016.pdfGuidance for State Medical Cannabis Testing
MTBC Drug Susceptibility Testing: EMBhttp://redesign.dev.aphl.org/aboutAPHL/publications/Documents/ID-MTBC_DrugSusceptibility_0216.pdfMTBC Drug Susceptibility Testing: EMBA discussion of issues surrounding the use of the anti-tuberculosis drug Ethambutol, or EMB, including recommended dose, EMB drug susceptibility testing and test methods, and reproducibility of susceptibility testing for EMB.
MTBC Drug Susceptibility Testing: PZAhttp://redesign.dev.aphl.org/aboutAPHL/publications/Documents/ID-PZA_WhitePaper_0216.pdfMTBC Drug Susceptibility Testing: PZAA discussion about the use of Pyrazinimide, or PZA, as first-line therapy for treatment of Mycobacterium tuberculosis complex, including mechanism of action, reproducibility of susceptibility testing, and impact on clinical outcomes.